source
- Valneva sees LimmaTech vaccine reduce Shigella infections in phase 2 testValneva’s Shigella vaccine has been shown to reduce cases of intestinal infection, hitting the key endpoint of a phase 2 trial.Fierce Biotech · 5h ago↗ source
- Argenx inks $1.15B Unnatural Products buyout to expand in oral peptidesArgenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech to add oral peptide capabilities.Fierce Biotech · 6h ago↗ source
- Recent heart-drug trials miss endpoints, raising doubts about AI-driven drug designTwo large clinical studies presented at the American Heart Association meeting this weekend failed to show any benefit for experimental heart‑attack and stroke therapies, underscoring the difficult…